Replimune Group Reports $83.1 Million Net Loss in Q2 Fiscal 2025

Replimune Group, Inc. reported significant financial results for the second quarter of fiscal year 2025, ending September 30, 2025, with a net loss of $83.1 million, compared to a net loss of $53.1 million for the same period in 2024. For the six months ended September 30, 2025, the company recorded a net loss of $169.8 million, up from $106.8 million in the prior year. The increase in losses is attributed primarily to higher operating expenses, which totaled $84.3 million for the quarter, a 43% increase from $58.9 million in the previous year. Research and development expenses rose to $57.9 million, up from $43.4 million, reflecting increased costs associated with clinical trials and personnel.

The company’s total assets decreased to $389.5 million as of September 30, 2025, down from $551.3 million at the end of the previous fiscal year. This decline was driven by a reduction in cash and short-term investments, which fell from $483.8 million to $323.6 million. Replimune's accumulated deficit also increased to $1.12 billion, highlighting the ongoing financial challenges faced by the company as it continues to invest heavily in its product development pipeline.

Strategically, Replimune has made notable advancements in its clinical programs, particularly with its lead product candidate, RP1, which is currently under review by the FDA following a resubmission of its Biologics License Application (BLA) for the treatment of advanced melanoma. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of April 10, 2026, for this resubmission. The company is also actively conducting multiple clinical trials, including the IGNYTE-3 trial, which aims to evaluate RP1 in combination with nivolumab in patients who have failed prior anti-PD-1 therapies.

Operationally, Replimune has expanded its workforce to support its growing clinical and commercial activities, with an increase in employee headcount contributing to higher personnel costs. The company is also focused on enhancing its manufacturing capabilities and preparing for potential commercialization of RP1. As of September 30, 2025, Replimune had cash and cash equivalents sufficient to fund operations through at least the next 12 months, although the company cautioned that its future capital needs may require additional financing through equity offerings or collaborations.

Looking ahead, Replimune remains committed to advancing its clinical programs and achieving regulatory approvals for its product candidates. However, the company acknowledges the inherent risks and uncertainties in the biotechnology sector, including the potential need to adjust its development plans based on regulatory feedback and market conditions. The successful commercialization of RP1 and other candidates will be critical for the company to achieve profitability and sustain its operations in the long term.